Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Alice Long

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
JCI Insight|November 1, 2019
A composite immune signature parallels disease progression across T1D subjectsCate Speake, Samuel O Skinner, Dror Berel, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
American Journal of Respiratory Cell and Molecular Biology|July 1, 2024
PD-L1 and PD-1 Are Associated with Clinical Outcomes and Alveolar Immune Cell Activation in Acute Respiratory Distress SyndromeEric D Morrell, Sarah E Holton, Alice Wiedeman, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Cell Reports. Medicine|November 2, 2023
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetesEmily K Sims, Abhishek Kulkarni, Audrey Hull, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
Communications Medicine|April 6, 2024
Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic reviewJamie L Felton, Maria J Redondo, Richard A Oram, et al.
Diabetes|April 11, 2019
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA<sub>1c</sub>, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J Haller, S Alice Long, J Lori Blanchfield, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
JCI Insight|November 1, 2019
A composite immune signature parallels disease progression across T1D subjectsCate Speake, Samuel O Skinner, Dror Berel, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
American Journal of Respiratory Cell and Molecular Biology|July 1, 2024
PD-L1 and PD-1 Are Associated with Clinical Outcomes and Alveolar Immune Cell Activation in Acute Respiratory Distress SyndromeEric D Morrell, Sarah E Holton, Alice Wiedeman, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Cell Reports. Medicine|November 2, 2023
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetesEmily K Sims, Abhishek Kulkarni, Audrey Hull, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
Communications Medicine|April 6, 2024
Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic reviewJamie L Felton, Maria J Redondo, Richard A Oram, et al.
Diabetes|April 11, 2019
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA<sub>1c</sub>, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J Haller, S Alice Long, J Lori Blanchfield, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
Pageof 8